Navigation Links
Cancer drug protects against diabetes
Date:1/9/2014

Very low doses of a drug used to treat certain types of cancer protect the insulin-producing cells in the pancreas and prevent the development of diabetes mellitus type 1 in mice. The medicine works by lowering the level of so-called sterile inflammation. The findings have been made by researchers from the University of Copenhagen, the Technical University of Denmark and the University of Southern Denmark working with researchers in Belgium, Italy, Canada, Netherlands and the USA.

"Diabetes is a growing problem worldwide. Our research shows that very low doses of anticancer drugs used to treat lymphoma so-called lysine deacetylase inhibitors can reset the immune response to not attack the insulin-producing cells. We find fewer immune cells in the pancreas, and more insulin is produced when we give the medicine in the drinking water to mice that would otherwise develop type 1 diabetes," says postdoc Dan Ploug Christensen, who is the first author on the article and responsible for the part of the experimental work carried out in Professor Thomas Mandrup-Poulsen's laboratory at the Department of Biomedical Sciences, University of Copenhagen.

The ground-breaking findings have just been published in the scientific journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

From mice to men

"This type of medicine is already being used against certain cancers, but we used doses which are 100 times lower than those used in cancer treatment and which have been shown to be safe in children with certain rheumatic diseases," says Thomas Mandrup-Poulsen.

"Our results are a step towards developing a preventive treatment for type 1 diabetes," says Dan Ploug Christensen. "It works by blocking the molecules that send the harmful inflammation signals into the insulin-producing cells. In doing so, it prevents the cells from producing a number of factors which contribute to destroying the cells when exposed to inflammation."

The researchers have subjected insulin-producing tissue from organ donors to the inflammation signals and shown that cancer medicine also delays the destruction of human cells. "The next step is clinical trials to test whether the drug also has an effect on people at risk of developing type 1 diabetes, for example close family members to patients with the disease," says Thomas Mandrup-Poulsen.

No cure is available for type 1 diabetes, which has to be treated with several insulin injections a day. In Denmark, the incidence of type 1 diabetes is increasing by approx. 3 per cent a year.


'/>"/>

Contact: Dan Ploug Christensen
dploug@sund.ku.dk
45-25-34-55-44
University of Copenhagen
Source:Eurekalert

Related biology news :

1. Researchers discover a tumor suppressor gene in a very aggressive lung cancer
2. Novel noninvasive therapy prevents breast cancer formation in mice
3. UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer
4. International team completes systematic, genomic study of cervical cancer
5. Breast cancer patients experience fewer side effects from anticancer drug when receiving acupuncture
6. A new role for milk: Delivering polyphenols with anti-cancer activity
7. The first cancer operation room with a navigator is created
8. New compound could reverse loss of muscle mass in cancer and other diseases
9. Role for sugar uptake in breast cancer revealed
10. Muscle-invasive and non-muscle invasive bladder cancers arise from different stem cells
11. Spontaneous fusion with macrophages empowers cancer cells to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology: